[Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer 
with Rare Mutation]

Area of Science:

• Oncology
• Genetics
• Immunotherapy

Background:

• Targeted therapies have transformed non-small cell lung cancer (NSCLC) treatment for common oncogene drivers.
• Limited targeted drug options exist for NSCLC patients with rare mutations (e.g., BRAF, HER2, MET, RET).
• Immune checkpoint inhibitors (ICIs) are emerging as a significant treatment modality in NSCLC.

Purpose of the Study:

• To review the current efficacy of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) patients with rare mutations.
• To consolidate real-world evidence due to the challenges in conducting prospective trials for rare mutations.
• To provide guidance for the rational application of ICIs in this specific NSCLC population.

Main Methods:

• Systematic review of available real-world studies.
• Analysis of clinical evidence from retrospective studies and case series.
• Focus on studies with convincing clinical data regarding ICI efficacy.

Main Results:

• Efficacy data for ICIs in NSCLC with rare mutations is currently limited but growing.
• Real-world studies suggest potential benefit of ICIs in certain rare mutation subgroups.
• Further research is needed to precisely define ICI effectiveness across diverse rare mutations.

Conclusions:

• Immune checkpoint inhibitors (ICIs) represent a potential therapeutic avenue for non-small cell lung cancer (NSCLC) with rare mutations.
• Real-world data is crucial for understanding ICI efficacy in these challenging cases.
• Rational use of ICIs in NSCLC with rare mutations can be facilitated by evidence synthesis.